A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs
CONCLUSION: Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.PMID:38465482 | DOI:10.1111/vde.13246 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - March 11, 2024 Category: Veterinary Research Authors: Laura Sch äfer Nina Thom Source Type: research
A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs
CONCLUSION: Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.PMID:38465482 | DOI:10.1111/vde.13246 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - March 11, 2024 Category: Veterinary Research Authors: Laura Sch äfer Nina Thom Source Type: research
A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs
CONCLUSION: Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.PMID:38465482 | DOI:10.1111/vde.13246 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - March 11, 2024 Category: Veterinary Research Authors: Laura Sch äfer Nina Thom Source Type: research
A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs
CONCLUSION: Oral supplementation of PUFA allowed dose reduction of oclacitinib and improved PVAS, QoL, QoC and GA. The use of PUFA is recommended and was safe in the atopic study dogs receiving oclacitinib.PMID:38465482 | DOI:10.1111/vde.13246 (Source: Veterinary Dermatology)
Source: Veterinary Dermatology - March 11, 2024 Category: Veterinary Research Authors: Laura Sch äfer Nina Thom Source Type: research
Relapsing eosinophilic pneumonia in a patient with recurrent breast cancer receiving abemaciclib plus endocrine therapy
This report presents the case of a 42-year-old Japanese woman with recurrent hormone receptor –positive breast cancer who developed eosinophilic pneumonia (EP) during treatment with abemaciclib combined with endocrine therapy. Seven years after a radical surgery and definite diagnosis of Stage I breast cancer, her cancer recurred with metastases to multiple organs. Initially treated with a bemaciclib plus letrozole and goserelin for 3 months, she developed EP, which improved after the discontinuation of anti-cancer treatment and the administration of prednisolone. However, EP occurred again upon the reintroduction of end...
Source: Respirology Case Reports - March 7, 2024 Category: Respiratory Medicine Authors: Hiroaki Ogata,
Chinami Koga,
Toyoshi Yanagihara,
Yuki Moriuchi,
Aimi Enokizu ‐Ogawa,
Akiko Ishimatsu,
Junji Otsuka,
Kazuhito Taguchi,
Atsushi Moriwaki,
Eriko Tokunaga,
Makoto Yoshida Tags: CASE REPORT Source Type: research
Comparison of the outcomes of Pneumocystis jirovecii pneumonia in rheumatoid arthritis patients treated with and without biologics
CONCLUSIONS: Biologic use before PCP onset did not increase the severity and mortality of PCP compared to non-biologics use in patients with RA.PMID:38452442 | DOI:10.1016/j.resinv.2024.02.015 (Source: Respiratory Care)
Source: Respiratory Care - March 7, 2024 Category: Respiratory Medicine Authors: Shin-Ichiro Ohmura Hiroki Matsui Toshiaki Miyamoto Daisuke Shichi Takayuki Masui Katsutoshi Ichijo Yuya Homma Haruka Fujioka Tatsuya Nagai Kei Nakashima Source Type: research
Risks of infection and severity of coronavirus disease 2019 in kidney transplant recipients: A single-center cohort study
CONCLUSION: In kidney transplant recipients, the infection rate and severity of COVID-19 tended to increase with higher maintenance doses of steroids. Recipients taking >5 mg of prednisolone should be considered a switch from tacrolimus to cyclosporine because cyclosporine may inhibit viral replication and reduce the risk of infection.PMID:38452985 | DOI:10.1016/j.trim.2024.102023 (Source: Transplant Immunology)
Source: Transplant Immunology - March 7, 2024 Category: Transplant Surgery Authors: Kuniaki Inoue Shunta Hori Mitsuru Tomizawa Tatsuo Yoneda Yasushi Nakai Makito Miyake Nobumichi Tanaka Kiyohide Fujimoto Source Type: research
Risks of infection and severity of coronavirus disease 2019 in kidney transplant recipients: A single-center cohort study
CONCLUSION: In kidney transplant recipients, the infection rate and severity of COVID-19 tended to increase with higher maintenance doses of steroids. Recipients taking >5 mg of prednisolone should be considered a switch from tacrolimus to cyclosporine because cyclosporine may inhibit viral replication and reduce the risk of infection.PMID:38452985 | DOI:10.1016/j.trim.2024.102023 (Source: Transplant Immunology)
Source: Transplant Immunology - March 7, 2024 Category: Transplant Surgery Authors: Kuniaki Inoue Shunta Hori Mitsuru Tomizawa Tatsuo Yoneda Yasushi Nakai Makito Miyake Nobumichi Tanaka Kiyohide Fujimoto Source Type: research
Risks of infection and severity of coronavirus disease 2019 in kidney transplant recipients: A single-center cohort study
CONCLUSION: In kidney transplant recipients, the infection rate and severity of COVID-19 tended to increase with higher maintenance doses of steroids. Recipients taking >5 mg of prednisolone should be considered a switch from tacrolimus to cyclosporine because cyclosporine may inhibit viral replication and reduce the risk of infection.PMID:38452985 | DOI:10.1016/j.trim.2024.102023 (Source: Transplant Immunology)
Source: Transplant Immunology - March 7, 2024 Category: Transplant Surgery Authors: Kuniaki Inoue Shunta Hori Mitsuru Tomizawa Tatsuo Yoneda Yasushi Nakai Makito Miyake Nobumichi Tanaka Kiyohide Fujimoto Source Type: research
Risks of infection and severity of coronavirus disease 2019 in kidney transplant recipients: A single-center cohort study
CONCLUSION: In kidney transplant recipients, the infection rate and severity of COVID-19 tended to increase with higher maintenance doses of steroids. Recipients taking >5 mg of prednisolone should be considered a switch from tacrolimus to cyclosporine because cyclosporine may inhibit viral replication and reduce the risk of infection.PMID:38452985 | DOI:10.1016/j.trim.2024.102023 (Source: Transplant Immunology)
Source: Transplant Immunology - March 7, 2024 Category: Transplant Surgery Authors: Kuniaki Inoue Shunta Hori Mitsuru Tomizawa Tatsuo Yoneda Yasushi Nakai Makito Miyake Nobumichi Tanaka Kiyohide Fujimoto Source Type: research
Risks of infection and severity of coronavirus disease 2019 in kidney transplant recipients: A single-center cohort study
CONCLUSION: In kidney transplant recipients, the infection rate and severity of COVID-19 tended to increase with higher maintenance doses of steroids. Recipients taking >5 mg of prednisolone should be considered a switch from tacrolimus to cyclosporine because cyclosporine may inhibit viral replication and reduce the risk of infection.PMID:38452985 | DOI:10.1016/j.trim.2024.102023 (Source: Transplant Immunology)
Source: Transplant Immunology - March 7, 2024 Category: Transplant Surgery Authors: Kuniaki Inoue Shunta Hori Mitsuru Tomizawa Tatsuo Yoneda Yasushi Nakai Makito Miyake Nobumichi Tanaka Kiyohide Fujimoto Source Type: research
Risks of infection and severity of coronavirus disease 2019 in kidney transplant recipients: A single-center cohort study
CONCLUSION: In kidney transplant recipients, the infection rate and severity of COVID-19 tended to increase with higher maintenance doses of steroids. Recipients taking >5 mg of prednisolone should be considered a switch from tacrolimus to cyclosporine because cyclosporine may inhibit viral replication and reduce the risk of infection.PMID:38452985 | DOI:10.1016/j.trim.2024.102023 (Source: Transplant Immunology)
Source: Transplant Immunology - March 7, 2024 Category: Transplant Surgery Authors: Kuniaki Inoue Shunta Hori Mitsuru Tomizawa Tatsuo Yoneda Yasushi Nakai Makito Miyake Nobumichi Tanaka Kiyohide Fujimoto Source Type: research
Two acute kidney injury episodes after ICI therapy: a case report
AbstractA 74-year-old Japanese male with lung squamous cell carcinoma received his first dose of immune checkpoint inhibitors (ICIs): ipilimumab and nivolumab. He developed acute kidney injury (AKI) and was admitted to our department. We diagnosed kidney immune-related adverse effects (irAE), and a kidney biopsy revealed acute tubulointerstitial nephritis. We started oral prednisolone (PSL) and his AKI immediately improved. The patient maintained stable findings after PSL was tapered off. However, seven months after the ICI administration, he developed rapid progressive glomerular nephritis and was admitted to our departme...
Source: CEN Case Reports - March 7, 2024 Category: Urology & Nephrology Source Type: research
Case report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin's disease developing resistance to pembrolizumab
In conclusion, we demonstrate for the first time that MEPED therapy is highly effective in a patient with Hodgkin's disease who has been refractory to ICPi. Sustained CR was achieved over 11 months after initiation of MEPED therapy. Further studies on a larger patient cohort should be performed.PMID:38444946 | PMC:PMC10912635 | DOI:10.3389/fphar.2024.1334233 (Source: Cancer Control)
Source: Cancer Control - March 6, 2024 Category: Cancer & Oncology Authors: K Reuthner P Aubele K Menhart P Rath D C Harrer W Herr J Hahn M Vogelhuber D Heudobler F Lueke A Reichle M Grube Source Type: research
Glucocorticoid discontinuation rate and risk factors for relapses in a contemporary cohort of patients with giant cell arteritis
AbstractThe rates of relapses and therapy discontinuation in patients with giant cell arteritis (GCA) in the modern therapeutic era have not been defined. We aimed to evaluate the glucocorticoid (GC) discontinuation rate and the factors associated with relapses in a contemporary GCA cohort. Patient and treatment data were collected cross-sectionally at first evaluation and 2 years later (second evaluation), in a multicenter, prospective GCA cohort. Predictors of relapses were identified by logistic regression analyses. 243 patients with GCA were initially included (67% women, mean age at diagnosis: 72.1 years, median disea...
Source: Rheumatology International - March 5, 2024 Category: Rheumatology Source Type: research
